Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incidence and risk factors of linezolid- vs vancomycin-associated lactic acidosis
ChiCTR2200061333Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2022
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in sepsis and Gram-positive bacterial infection comparing Linezolid arm with Vancomycin arm (2 arms). Primary endpoints: Blood lactic acid level and Mortality. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
linezolidvancomycin
03
Conditions
sepsisGram-positive bacterial infection
Beyond the preview
Go deeper on ChiCTR2200061333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061333.